Powder: -20°C for 3 years | In solvent: -80°C for 1 year
RK-24466 (KIN 001-51) 是高效的、选择性的 Lck 抑制剂,对 Lck (64-509) 和 LckCD 亚型的 IC50 值分别为小于 1 和2 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 617 | 现货 | ||
5 mg | ¥ 1,470 | 现货 | ||
10 mg | ¥ 2,390 | 现货 | ||
25 mg | ¥ 3,970 | 现货 | ||
50 mg | ¥ 5,780 | 现货 | ||
100 mg | ¥ 7,880 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,620 | 现货 |
产品描述 | RK-24466 (KIN 001-51) is a selective and potent inhibitor of Lck, inhibits Lck (64-509) and LckCD isoforms with IC50s of less than 1 and 2 nM, respectively. |
靶点活性 | LckCD:2 nM (IC50), Lck (64-509):<1 nM (IC50) |
体外活性 | RK-24466, a lymphocyte-specific protein tyrosine kinase (Lck) inhibitor, significantly inhibited both VSMC proliferation and migration. RK-24466 suppresses VSMC proliferation and migration via down-regulating the protein kinase B (Akt) and extracellular signal regulated kinase (ERK) pathways, and it significantly decreased the expression of proliferating cell nuclear antigen (PCNA) and cyclin D1 and, the phosphorylation of retinoblastoma protein (pRb). Additionally, RK-24466 suppressed the migration of VSMCs from endothelium-removed aortic rings, as well as neointima formation following rat carotid balloon injury. The present study identified RK-24466 as a potent VSMC proliferation and migration inhibitor and warrants further studies to elucidate its more detailed molecular mechanisms, such as its primary target, and to further validate its in vivo efficacy as a therapeutic agent for pathologic vascular conditions, such as restenosis and atherosclerosis[1]. |
别名 | KIN 001-51 |
分子量 | 370.45 |
分子式 | C23H22N4O |
CAS No. | 213743-31-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 40 mg/mL (107.97 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.6994 mL | 13.4971 mL | 26.9942 mL | 67.4855 mL |
5 mM | 0.5399 mL | 2.6994 mL | 5.3988 mL | 13.4971 mL | |
10 mM | 0.2699 mL | 1.3497 mL | 2.6994 mL | 6.7485 mL | |
20 mM | 0.135 mL | 0.6749 mL | 1.3497 mL | 3.3743 mL | |
50 mM | 0.054 mL | 0.2699 mL | 0.5399 mL | 1.3497 mL | |
100 mM | 0.027 mL | 0.135 mL | 0.2699 mL | 0.6749 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
RK-24466 213743-31-8 Angiogenesis Tyrosine Kinase/Adaptors Src Inhibitor inhibit RK 24466 KIN 001-51 RK24466 inhibitor